Updated results from a trial with belzutifan for people with advanced kidney cancer
Kidney cancers frequently have mutations in the von Hippel-Lindau (VHL) gene, [...]
Treatment of kidney masses in patients with VHL disease
In this video interview, Dr Eric Jonasch from MD Anderson [...]
HIF2α inhibitor provides significant clinical benefit in patients with VHL kidney cancer
One of the major breakthroughs this year the hypoxia-inducible factor [...]
Future for VHL kidney cancer is bright
Von Hippel-Lindau (VHL) disease–associated renal cell carcinoma (RCC) has always [...]
ASCO 2020: HIF-2 alpha inhibitor induced positive response for VHL-associated kidney cancer
Results from a phase II international trial led by researchers [...]
VHL disease and HIF-2alpha inhibitor
In this video interview, Dr Eric Jonasch from MD Anderson [...]
Hereditary kidney cancer – new syndromes
A recent review of the literature in European Urology summarises [...]
Potential new treatment strategy for kidney cancer
A research study, published online in eLife, has provided new [...]
ESMO 2018: Interviews with the kidney cancer experts
The following video interviews with kidney cancer experts from the [...]
Von Hippel-Lindau (VHL) disease and the risk for kidney cancer
Von Hippel-Lindau (VHL) disease is caused by a change (mutation) [...]
